| | | | | | | | | | | | | | | | |
| |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| 2025 | 2022 | NANOCAN THERAPEUTICS CORPORATION | 900 NEW HAMPSHIRE AVE NW | WASHINGTON | DC | 20037-2301 | DISTRICT OF COLUMBIA | USA | R42CA272056 | Radio-immunotherapy dose-painting (RAID) treatment for hormonal resistant prostate cancer | 000 | 1 | NIH | 3/26/2025 | $0 |
|
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| 2024 | 2022 | NANOCAN THERAPEUTICS CORPORATION | 900 NEW HAMPSHIRE AVE NW | WASHINGTON | DC | 20037-2301 | DISTRICT OF COLUMBIA | USA | R42CA272056 | Radio-immunotherapy dose-painting (RAID) treatment for hormonal resistant prostate cancer | 000 | 1 | NIH | 11/15/2023 | $0 |
| 2024 | 2022 | NANOCAN THERAPEUTICS CORPORATION | 900 NEW HAMPSHIRE AVE NW | WASHINGTON | DC | 20037-2301 | DISTRICT OF COLUMBIA | USA | R41CA268623 | Liquid Immunogenic Fiducial Eluter (LIFE) for Cervical Cancer Treatment | 000 | 1 | NIH | 7/19/2024 | $0 |
|
 | Issue Date FY: 2023 ( Subtotal = $0 ) |
| 2023 | 2022 | NANOCAN THERAPEUTICS CORPORATION | 103 CARNEGIE CTR STE 300 | PRINCETON | NJ | 08540-6235 | MERCER | USA | R41CA268623 | Liquid Immunogenic Fiducial Eluter (LIFE) for Cervical Cancer Treatment | 000 | 1 | NIH | 10/21/2022 | $0 |
| 2023 | 2022 | NANOCAN THERAPEUTICS CORPORATION | 103 CARNEGIE CTR STE 300 | PRINCETON | NJ | 08540-6235 | MERCER | USA | R42CA272056 | Radio-immunotherapy dose-painting (RAID) treatment for hormonal resistant prostate cancer | 001 | 1 | NIH | 12/5/2022 | $0 |
| 2023 | 2022 | NANOCAN THERAPEUTICS CORPORATION | 103 CARNEGIE CTR STE 300 | PRINCETON | NJ | 08540-6235 | MERCER | USA | R42CA272056 | Radio-immunotherapy dose-painting (RAID) treatment for hormonal resistant prostate cancer | 000 | 1 | NIH | 11/21/2022 | $0 |
|
 | Issue Date FY: 2022 ( Subtotal = $799,680 ) |
| 2022 | 2022 | NANOCAN THERAPEUTICS CORPORATION | 103 CARNEGIE CTR STE 300 | PRINCETON | NJ | 08540-6235 | MERCER | USA | R42CA272056 | Radio-immunotherapy dose-painting (RAID) treatment for hormonal resistant prostate cancer | 002 | 1 | NIH | 9/12/2022 | -$399,680 |
| 2022 | 2022 | NANOCAN THERAPEUTICS CORPORATION | 103 CARNEGIE CTR STE 300 | PRINCETON | NJ | 08540-6235 | MERCER | USA | R42CA272056 | Radio-immunotherapy dose-painting (RAID) treatment for hormonal resistant prostate cancer | 002 | 1 | NIH | 9/12/2022 | $399,680 |
| 2022 | 2022 | NANOCAN THERAPEUTICS CORPORATION | 103 CARNEGIE CTR STE 300 | PRINCETON | NJ | 08540-6235 | MERCER | USA | R42CA272056 | Radio-immunotherapy dose-painting (RAID) treatment for hormonal resistant prostate cancer | 000 | 1 | NIH | 5/6/2022 | $399,680 |
| 2022 | 2022 | NANOCAN THERAPEUTICS CORPORATION | 103 CARNEGIE CTR STE 300 | PRINCETON | NJ | 08540-6235 | MERCER | USA | R42CA272056 | Radio-immunotherapy dose-painting (RAID) treatment for hormonal resistant prostate cancer | 001 | 1 | NIH | 5/11/2022 | $0 |
| 2022 | 2022 | NANOCAN THERAPEUTICS CORPORATION | 103 CARNEGIE CTR STE 300 | PRINCETON | NJ | 08540-6235 | MERCER | USA | R41CA268623 | Liquid Immunogenic Fiducial Eluter (LIFE) for Cervical Cancer Treatment | 000 | 1 | NIH | 4/13/2022 | $400,000 |
|
|